HOME >> BIOLOGY >> NEWS
Successful progress launch paves the way for further scientific utilisation of the ISS by Europe

The Progress supply vehicle will take two days to reach the International Space Station, carrying experiment hardware for the Delta mission to be carried out by ESA's Dutch astronaut Andr Kuipers in April, Matroshka, a European experiment facility for measuring radiation levels to which astronauts are exposed in space, and hardware to allow the European Automated Transfer Vehicle (ATV) to dock with the Station.

Launched by a Soyuz rocket on mission 13P, the Progress spacecraft with the serial number M1-11 is due to dock with the International Space Station on 31 January at 14:19 Central European Time. The Progress-type spacecraft are currently serving as supply vehicles for the International Space Station and are also uploading European hardware and equipment in advance of European missions to be carried out on the International Space Station.

Among other cargo, Progress is transporting scientific equipment which will be used during the upcoming Delta mission (Dutch Expedition for Life science, Technology and Atmospheric research). Andr Kuipers, who on 19 April flies out to the ISS on a 10-day mission, will be employing this equipment to carry out a programme of scientific and educational activities. The Delta experiments on board Progress are:

ARGES: This experiment will study high-intensity discharge (HID) lamps, which are used in all kinds of outdoor illuminations, making use of the absence of gravity to get new insights into how these lamps work and help develop more efficient lamps in future.
HEAT: This experiment will be testing heat transfer properties in a section of a heat pipe with the aim of developing more efficient heat distribution systems for satellites and space vehicles in future.
PROMISS-3: The experiment aims to analyse the growth of protein crystals in weightlessness, which cannot be observed to the same extent and with the same homogeneity on the ground.
SUIT: The aims o
'"/>

Contact: Franco Bonacina
franco.bonacina@esa.int
33-1-53-69-7155
European Space Agency
29-Jan-2004


Page: 1 2 3 4

Related biology news :

1. Successful Green Solvent Found For Problematic Chemicals
2. University Of Pittsburgh Involved In First Successful Example Of Gene Therapy For Pain Control
3. Successful Hemophilia B Gene Therapy In Dogs May Justify Human Experiments
4. News Backgrounder: Duke Primate Center Successfully Fosters Mysterious Aye-Ayes
5. Successful Specialist Care For Cystic Fibrosis Patients From Childhood To Adulthood
6. New Treatment Successful With Hepatitis C
7. New RNA Repair May Lead To More Successful Gene Therapy
8. NIAID Doctor Successfully Treats Longest Case Of Malaria Infection On Record
9. Chlamydia Testing Of Urine Samples Can Be Successful
10. New molecular link key to cellular proteins involved in cancer progression, other diseases
11. A new protein is discovered to play a key role in cancer progression

Post Your Comments:
(Date:5/22/2013)... YORK, May 22, 2013. Plastic additives known as ... about everywhere: They turn up in flooring, plastic ... to the Centers for Disease Control and Preventionthe ... phthalates have come under increasing scrutiny. A growing ... (which can leech from packaging and mix with ...
(Date:5/21/2013)... infections occur in the body, stem cells in ... and differentiating into mature immune cells that can ... can deplete these cell populations, potentially leading to ... cancer. Now, a team of researchers led by ... has found that, in mouse models, the molecule ...
(Date:5/21/2013)... Widely available in pharmacies and health stores, phosphatidylserine ... oysters, and soy. Proven to improve cognition and ... older people experiencing memory impairment. Now a team ... Bochner of Tel Aviv University,s Department of ... same supplement improves the functioning of genes involved ...
Breaking Biology News(10 mins):Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2Keeping stem cells strong 2Common food supplement fights degenerative brain disorders 2
(Date:5/21/2013)... (PRWEB) May 21, 2013 ... services company for clinical trials, announced today it ... Solutions, LLC. Clinverse’s ClinPay® FLS eClinical commerce ... payment process. SpendMD ™, Aggregate Spend ... solution for tracking and reporting transfer of value ...
(Date:5/21/2013)... May 21, 2013 According to ... ( http://www.transparencymarketresearch.com ) "Biochip Products and Services Market (Microarrays, ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the ... and is expected to grow at a CAGR of ... value of USD 4.7 billion in 2018. ...
(Date:5/21/2013)... May 21, 2013 Many have long ... contributor to acne. Recently physicians from Clinical Psychiatry.com ... stress on the skin, and suggested using hypnotherapy ... the chemicals produced from stress that cause acne. , ... negative feelings acne brings about, stress causes changes in ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. ... study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal ... expressing the HER2 oncoprotein," will be presented at ... of Clinical Oncology during the Developmental Therapeutics - ... at 4:15 – 4:30 PM.  The presentation will ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: